Mark Boiskin, MD
Nephrology · la Jolla, CANPI 1437154143
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (49.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by CSL Behring at 39.1% of the total. Reporting peaked in 2024 at $1,746 and has fallen 85.7% since, to $249 in 2025.
Across 84 payments — averaging $53.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2K
- Merck$909
- AstraZeneca$394
- Otsuka America Pharmaceutical, Inc.$357
- Vifor Pharma, Inc.$253
- Nxstage Medical, Inc.$169
- plus $642 from 13 others
Across 1,065 payments — averaging $837.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$415K
- CSL Behring$342K
- AstraZeneca$67K
- Alnylam Pharmaceuticals Inc.$38K
- Bayer$12K
- Ardelyx, Inc.$10K
- plus $8K from 1 others
What the payments were for
- Travel & lodging$2,21249%
- Food & beverage$1,93843%
- Education$3207%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 8 | $1,746 |
| Merck | 7 | $909 |
| AstraZeneca | 20 | $394 |
| Otsuka America Pharmaceutical, Inc. | 6 | $357 |
| Vifor Pharma, Inc. | 11 | $253 |
| Nxstage Medical, Inc. | 3 | $169 |
| Amgen | 5 | $97 |
| OPKO Pharmaceuticals, LLC | 4 | $77 |
| Ardelyx, Inc. | 1 | $67 |
| Calliditas Therapeutics US Inc. | 3 | $62 |
| Novartis | 1 | $57 |
| Bayer | 3 | $56 |
| Aurinia Pharma U.S., Inc. | 3 | $56 |
| Akebia Therapeutics Inc | 3 | $52 |
| Kyowa Kirin, Inc. | 1 | $50 |
| GSK | 2 | $37 |
| Fresenius USA Marketing, Inc. | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JYNARQUE$191
How this compares
$4,469 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 289 | $241,417 |
| JardianceEmpagliflozin | 131 | $113,330 |
| VeltassaPatiromer Calcium Sorbitex | 89 | $91,696 |
| LokelmaSodium Zirconium Cyclosilicate | 112 | $65,808 |
| OzempicSemaglutide | 71 | $65,587 |
| KerendiaFinerenone | 57 | $61,882 |
| VelphoroSucroferric Oxyhydroxide | 19 | $36,058 |
| JanuviaSitagliptin Phosphate | 35 | $26,963 |
| InvokanaCanagliflozin | 17 | $20,839 |
| Sevelamer Carbonate | 75 | $17,775 |
| SpsSodium Polystyrene Sulfon/Sorb | 27 | $15,905 |
| MounjaroTirzepatide | 14 | $13,815 |
| DapagliflozinDapagliflozin Propanediol | 17 | $6,229 |
| Potassium Citrate ErPotassium Citrate | 42 | $3,120 |
| Paricalcitol | 19 | $3,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $394 | $307,225401 claims |
| BayerKerendia | $56 | $61,88257 claims |
| Fresenius USA Marketing, Inc.Velphoro | $16 | $36,05819 claims |
| MerckJanuvia | $909 | $26,96335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.
Other nephrology in la Jolla
- Dylan Steerla Jolla$48K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.